JP2008538583A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538583A5
JP2008538583A5 JP2008507988A JP2008507988A JP2008538583A5 JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5 JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5
Authority
JP
Japan
Prior art keywords
composition
subject
hydrogen
apathy
nefiracetam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008507988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538583A (ja
Filing date
Publication date
Priority claimed from US11/406,158 external-priority patent/US20060241144A1/en
Application filed filed Critical
Publication of JP2008538583A publication Critical patent/JP2008538583A/ja
Publication of JP2008538583A5 publication Critical patent/JP2008538583A5/ja
Withdrawn legal-status Critical Current

Links

JP2008507988A 2005-04-20 2006-04-19 アパシー症候群を治療するための方法 Withdrawn JP2008538583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67355505P 2005-04-20 2005-04-20
US11/406,158 US20060241144A1 (en) 2005-04-20 2006-04-17 Method for treating apathy syndrome
PCT/US2006/015513 WO2006113937A2 (en) 2005-04-20 2006-04-19 Method for treating apathy syndrome

Publications (2)

Publication Number Publication Date
JP2008538583A JP2008538583A (ja) 2008-10-30
JP2008538583A5 true JP2008538583A5 (enExample) 2009-06-04

Family

ID=37115988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507988A Withdrawn JP2008538583A (ja) 2005-04-20 2006-04-19 アパシー症候群を治療するための方法

Country Status (4)

Country Link
US (2) US20060241144A1 (enExample)
EP (1) EP1874300B1 (enExample)
JP (1) JP2008538583A (enExample)
WO (1) WO2006113937A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002923A1 (en) * 2007-06-22 2008-12-31 The Research Foundation Of State University Of New York Substituted pyrrolidine compounds with central nervous system activity
ES2664727T3 (es) 2009-10-22 2018-04-23 University College Dublin National University Of Ireland, Dublin Terapia causal de enfermedades o estados asociados con desmielinización del SNC o del SNP
WO2012109491A1 (en) * 2011-02-09 2012-08-16 The Johns Hopkins University Methods and compositions for improving cognitive function
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103044307A (zh) * 2013-01-24 2013-04-17 吉林三善恩科技开发有限公司 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
CN106511307B (zh) * 2015-09-11 2018-10-23 重庆润泽医药有限公司 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法
CN106619530A (zh) * 2015-10-27 2017-05-10 重庆润泽医药有限公司 一种左旋奥拉西坦颗粒及其制备方法
CN106890154B (zh) * 2015-12-17 2018-10-23 重庆润泽医药有限公司 一种左旋奥拉西坦泡腾片及其制备方法
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
US5461157A (en) * 1992-06-19 1995-10-24 Daiichi Pharmaceutical Co., Ltd. Process for preparing pyrrolidinylacetamide derivatives
DE69623943T2 (de) * 1995-03-23 2003-08-07 Daiichi Pharmaceutical Co., Ltd. Wasserfreie kristalle
ES2233971T3 (es) * 1995-07-21 2005-06-16 Daiichi Pharmaceutical Co., Ltd. Procedimiento de produccion de una preparacion granular.
US6107330A (en) * 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
EP0953356A4 (en) * 1996-10-01 2002-04-17 Daiichi Seiyaku Co MITOCHONDRIAL MEMBRANE STABILIZER
AU8131198A (en) * 1997-07-15 1999-02-10 Daiichi Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for amnesia
AR020115A1 (es) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
CN1484527A (zh) * 2000-12-28 2004-03-24 ��һ��������ҩ��ʽ���� 神经性疼痛治疗和预防药
US20040192759A1 (en) * 2001-08-22 2004-09-30 Eiichi Otomo Use of nefiracetam for treating neurodegeneration

Similar Documents

Publication Publication Date Title
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
CN1084618C (zh) 5－羟色胺拮抗剂的新应用
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP2007520520A5 (enExample)
JP5925065B2 (ja) 医薬組成物
JP2008195730A5 (enExample)
JP2007145875A5 (enExample)
HUP0204526A2 (hu) 2-Oxo-1-pirrolidin-származékok, eljárás előállításukra és alkalmazásuk
JP2006517939A5 (enExample)
JP2010534647A5 (enExample)
JP2006525276A5 (enExample)
JP2008513496A5 (enExample)
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
JP2020507602A5 (enExample)
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
US20250228838A1 (en) Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2012515763A5 (enExample)
MA28111A1 (fr) Derives des
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
JP2016537432A5 (enExample)
JP2004523557A5 (enExample)
JP2022527618A5 (enExample)
RU2311408C2 (ru) Производные аминотетралина в качестве антагонистов мускаринового рецептора
US20060241144A1 (en) Method for treating apathy syndrome